

Comparison of Multi-gene Breast Cancer Tests Informing Adjuvant Treatment Decisions		Exact Sciences Oncotype DX <sup>®</sup>	Aggenia MammaPrint <sup>®</sup>	NanoString Prosigna <sup>®</sup>	bioTheranostics Breast Cancer Index <sup>SM</sup>	Myriad EndoPredict <sup>®</sup>
<b>Randomized Clinical Trials</b>	Number of Patients Randomized • Oncotype DX: TAILORx <sup>1</sup> (9-yr results)= 6711 • MammaPrint/MINDACT <sup>2</sup> (5-year results)= 2187	<b>N=6711</b>	N=2187			
<b>Validated for Prediction of Chemotherapy Benefit<sup>3,4</sup> (N- and N+)*</b>		✓				
<b>Validated for Prognosis<sup>4-8</sup></b>	Node Negative and Node Positive	✓	✓	✓	✓	✓
	Pre-Menopausal	✓	✓		✓	✓
	Post-Menopausal	✓	✓	✓	✓	✓
	Homogeneous Populations	✓		✓	✓	✓
<b>Inclusion in Major International Guidelines</b>	NCCN <sup>9</sup> Algorithm <sup>18</sup> :Strongly Consider**	✓				
	NCCN <sup>9</sup> Category <sup>18</sup> :Preferred*	✓				
	NICE (UK) Diagnostics Guidance <sup>19</sup>	✓				
	ASCO <sup>20-21</sup>	✓	✓	✓		✓
	ESMO <sup>22</sup> , St. Gallen <sup>23</sup> and AGO <sup>24</sup>	✓	✓	✓		✓
<b>Inclusion in AJCC 8th Edition Cancer Staging Table for assignment of Pathological Prognostic Stage Group 1A<sup>25</sup></b>		✓				
<b>Supportive &amp; Prospective Outcomes Evidence (number of N- &amp; N+ patients)</b>		<b>&gt;96,000<sup>9-13</sup></b>	>7,000 <sup>14-17</sup>			
<b>Additional Clinical Validation Evidence</b>		DCIS, Neoadjuvant, Late Recurrence, Adjuvant Hormonal Therapy Benefit	Neoadjuvant	Neoadjuvant, Late Recurrence	Late Recurrence, Extended Hormonal Therapy Benefit	Late Recurrence

\*Prediction of chemotherapy benefit versus treatment with endocrine therapy alone

\*\*Node-Negative, Hormone Receptor-Positive, HER2-Negative disease.

NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Breast Cancer V.3.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed March 6, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. ASCO is a trademark of the American Society of Clinical Oncology. AJCC is a trademark of the American College of Surgeons. NCCN, ASCO, ESMO, St. Gallen, NICE, AGO and AJCC do not endorse any product or therapy. **References:** 1. Sparano et al. *N Engl J Med.* 2018. 2. Cardoso et al. *N Engl J Med.* 2016. 3. Markopoulos et al. *Eur J Surg Oncol.* 2019. 4. Hyams et al. *J Surg Oncol.* 2017. 5. Filipits et al. *Clin Cancer Res.* 2011. 6. Martin et al. *Breast Cancer Research.* 2014. 7. Sgroi et al. *Lancet Oncol.* 2013. 8. Zhang et al. *Clin Cancer Res.* 2013. 9. Sparano et al. *N Engl J Med.* 2015. 10. Petkov et al. *npj Breast Cancer.* 2016. 11. Hortobagyi et al. SABCS 2018. 12. Stemmer et al. *npj Breast Cancer.* 2019. 13. Roberts et al. *Breast Cancer Res Treat.* 2017. 14. Drukker et al. *Int J Cancer.* 2013. 15. van de Vijver et al. *N Engl J Med.* 2002. 16. Buysse et al. *J Natl Cancer Inst.* 2006. 17. Esserman et al. *JAMA Oncol.* 2017. 18. NCCN Clinical Practice Guidelines in Oncology. V.3.2020. 19. NICE Diagnostics Guidance DG34. December 2018. 20. Andre et al. *J Clin Oncol.* 2019. 21. Krop et al. *J Clin Oncol.* 2017. 22. Cardoso et al. *Ann Oncol.* 2019. 23. Burstein et al. *Ann Oncol.* 2019. 24. www.ago-online.de Guidelines Breast Cancer Version 21.11.2018. 25. AJCC Cancer Staging Manual, Eighth Edition updated 9-Nov-17.

Oncotype DX Breast Recurrences Score, Oncotype DX, are trademarks of Genomic Health Inc, an Exact Sciences corporation.  
© 2020 Genomic Health Inc., an Exact Sciences corporation. All rights reserved. GH110984\_Q220

**TAILORx:**

Definitive results,  
consistent  
outcomes<sup>1-3</sup>



**YES**  
CHEMOTHERAPY

**NO**  
CHEMOTHERAPY

**It's never  
been as clear**

to predict chemotherapy benefit for  
patients with early-stage breast cancer<sup>1-4</sup>

*oncotype* **DX**<sup>®</sup>  
*Breast Recurrence Score*